These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11290888)

  • 1. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis.
    Toubert ME; Michel C; Metivier F; Peker MC; Rain JD
    Clin Nucl Med; 2001 Apr; 26(4):302-5. PubMed ID: 11290888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
    Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of iodine-131 ablation therapy for thyroid carcinoma in a patient on chronic hemodialysis].
    Zenasni N; Elkhayat S; Taleb S; Zamd M; Medkouri G; Benghanem Gharbi M; Ramdani B; Aschawa H; Guensi A
    Nephrol Ther; 2015 Apr; 11(2):114-7. PubMed ID: 25709102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
    Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
    Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.
    Khan SA; Khan MS; Arif M; Durr-e-Sabih ; Rahim MK; Ahmad I
    J Coll Physicians Surg Pak; 2015 Jul; 25(7):510-3. PubMed ID: 26208555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R; Thériault C; Del Vecchio P
    J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
    Randolph GW; Daniels GH
    Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
    Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report.
    Magné N; Magné J; Bracco J; Bussière F
    Jpn J Clin Oncol; 2002 Jun; 32(6):202-5. PubMed ID: 12110636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method.
    Jiménez RG; Moreno AS; Gonzalez EN; Simón FJL ; Rodriguez JR; Jimenez JC; Córdoba MH; Albertino RV; Jimenez RA
    Thyroid; 2001 Nov; 11(11):1031-4. PubMed ID: 11762712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP; Daver A; Minier JF; Larra F
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure.
    Yeyin N; Cavdar I; Uslu L; Abuqbeitah M; Demir M
    Nucl Med Commun; 2016 Mar; 37(3):283-7. PubMed ID: 26619394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
    Pahlka RB; Sonnad JR
    Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis.
    Daumerie C; Vynckier S; Caussin J; Jadoul M; Squifflet JP; de Patoul N; Wambersie A
    Thyroid; 1996 Aug; 6(4):301-4. PubMed ID: 8875750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy.
    Murcutt G; Edwards J; Boakye J; Davenport A
    Kidney Int; 2008 Jun; 73(11):1316-9. PubMed ID: 18354377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.